Assay for Inhibitors of Nonsense-Mediated RNA Decay

Tech ID: 27517 / UC Case 2016-708-0


An estimated 9 million people in the US suffer from genetic disorders that are a consequence of a nonsense or frameshift mutation that introduces a premature termination codon (PTC). PTC is also known as a nonsense codon or premature stop codon and such codons lead to loss of protein products. Nonsense-mediated RNA decay (NMD) is a cellular quality control mechanism to selectively degrade transcripts that have a PTC codon.

Currently exogenous assays are used to screen for compounds that inhibit NMD.These labor-intensive exogenous assays use PTC-containing reporter genes and are restricted to certain transfectable cells.  Since these reporter genes may not transfect the entire cell population in an assay, exogenous assays have limited sensitivity.  Exogenous reporters also have a high false positive rate, because these assays are simultaneously affected by non-NMD regulation.  Thus new and effective assays to screen for NMD inhibitors are desirable.

Brief Description

Prof. Sika Zheng at UCR has developed a new endogenous NMD assay that is both sensitive and quantitative. The assay can be used on its own to assess changes in cellular NMD activity with high specificity and sensitivity. It can facilitate analysis of NMD controls by cellular pathways in response to stimuli or during development and is particularly suitable for unbiased screening of NMD modulators. The assay is designed to distinguish NMD regulation from transcriptional regulation and alternative splicing control.



Fig. 1 shows the schematics of the novel endogenous assay that uses RT-qPCR methods to detect NMD and non-NMD isoform of the same gene. The NMD isoform can be the inclusion or the exclusion isoforms. The inclusion isoform is detected by primer F1 and isoform specific primer R1. The exclusion isoform is detected by F2 and isoform-specific junction primer R2. Primers F3 and R3 are commonly used in alternative splicing assays to detect both inclusion and exclusion isoforms.


Suggested uses

  • Use of endogenous NMD assay to screen for compounds and genes that modulate PTC and/or NMD


  • Simpler, faster, and less expensive than exogenous NMD assays
  • Ease of use in vivo or in tissue and organs without the need to transfect reporter genes into cells.

Related Materials

Patent Status

Country Type Number Dated Case
United States Of America Published Application 20180010188 01/11/2018 2016-708


Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information


NMD, nonsense-mediated RNA decay, inhibitor, assay, PTC, premature termination codon, stop codon, endogenous, exogenous

Categorized As